QuidelOrtho (NASDAQ:QDEL) Updates FY 2025 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 2.070-2.570 for the period, compared to the consensus EPS estimate of 2.380. The company issued revenue guidance of $2.6 billion-$2.8 billion, compared to the consensus revenue estimate of $2.7 billion.

QuidelOrtho Trading Up 0.4%

Shares of NASDAQ:QDEL traded up $0.11 during trading on Friday, reaching $28.81. 265,628 shares of the stock were exchanged, compared to its average volume of 1,091,325. The firm's 50-day moving average price is $29.77 and its 200 day moving average price is $36.04. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -5.81 and a beta of 0.10. QuidelOrtho has a 12-month low of $23.77 and a 12-month high of $49.45. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.66 and a current ratio of 1.20.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.13. QuidelOrtho had a negative net margin of 12.07% and a positive return on equity of 4.71%. The company had revenue of $692.80 million during the quarter, compared to the consensus estimate of $694.97 million. During the same period in the previous year, the firm earned $0.44 earnings per share. QuidelOrtho's revenue for the quarter was down 2.6% on a year-over-year basis. On average, sell-side analysts anticipate that QuidelOrtho will post 2.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

QDEL has been the subject of several analyst reports. Wall Street Zen raised QuidelOrtho from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. JPMorgan Chase & Co. reduced their price target on QuidelOrtho from $38.00 to $25.00 and set an "underweight" rating on the stock in a research report on Monday, April 21st. Jefferies Financial Group raised shares of QuidelOrtho from a "hold" rating to a "buy" rating and set a $44.00 price objective for the company in a research report on Thursday, May 8th. Finally, UBS Group reduced their target price on shares of QuidelOrtho from $45.00 to $29.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $44.33.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Focus Partners Wealth lifted its position in shares of QuidelOrtho by 210.9% during the first quarter. Focus Partners Wealth now owns 20,454 shares of the company's stock worth $715,000 after purchasing an additional 13,876 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in QuidelOrtho by 10.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 228,398 shares of the company's stock valued at $7,987,000 after buying an additional 21,968 shares during the last quarter. Finally, Royal Bank of Canada boosted its holdings in shares of QuidelOrtho by 1,218.7% during the first quarter. Royal Bank of Canada now owns 80,193 shares of the company's stock valued at $2,803,000 after acquiring an additional 74,112 shares during the period. 99.00% of the stock is currently owned by institutional investors.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.